Revance Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Revance Therapeutics generated cash of -$216,575,000, which is less than the previous year. Cash used in financing activities reached the amount of $136,567,000 last year. Net change in cash is therefore $29,732,000.
Cash Flow
| 2014 | -55.07M | -6.9M | 229.09M |
|---|---|---|---|
| 2015 | -55.66M | -56.34M | 142.59M |
| 2016 | -59.82M | -75.49M | -2.64M |
| 2017 | -95.34M | 118.79M | 195.94M |
| 2018 | -104.24M | -107.02M | 1.78M |
| 2019 | -106.16M | -17.59M | 221.65M |
| 2020 | -178.50M | 12.13M | 331.48M |
| 2021 | -221.53M | -29.66M | 29.86M |
| 2022 | -193.54M | -138.79M | 331.69M |
| 2023 | -216.57M | 109.74M | 136.56M |
RVNC Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 115.01M | 115.66M | 337.00M | 171.89M | 73.98M | 283.47M | 64.08M | 202.05M | 171.03M | 3.91M |
Operating activities | ||||||||||
Net income | -323.98M | -356.42M | -281.31M | -282.08M | -159.42M | -142.56M | -120.58M | -89.27M | -73.47M | -62.91M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 13.69M | 39.14M | 19.85M | 10.25M | 2.90M | 1.72M | 1.46M | 1.44M | 1.99M | 2.05M |
Stock-based compensation expense | 47.81M | 52.34M | 43.43M | 36.45M | 17.92M | 0 | 13.23M | 11.95M | 12.38M | 6.53M |
| Deferred income tax benefit | 47.81M | 52.34M | 43.43M | 36.45M | 17.92M | 0 | 13.23M | 11.95M | 12.38M | 6.53M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -16.33M | -7.99M | -1.51M | 12.13M | 27M | -26.95M | 80K | 0 | 0 | 0 |
Inventories | -14.91M | -6.00M | -4.27M | -5.87M | -27M | -3.17M | 0 | 0 | 0 | 0 |
Accounts payable | 6.9M | -5.44M | -1.82M | 4.42M | -360K | 1.69M | 2.60M | 953K | -692K | -3.39M |
Cash generated by operating activities | -216.57M | -193.54M | -221.53M | -178.50M | -106.16M | -104.24M | -95.34M | -59.82M | -55.66M | -55.07M |
Investing activities | ||||||||||
Purchases Of Investments | -263.92M | -347.96M | -183.59M | -259.30M | -331.36M | -314.91M | -36.02M | -280.68M | -54.08M | 0 |
Investments In Property Plant And Equipment | -6.88M | -23.01M | -18.07M | -4.21M | -3.23M | -7.09M | -2.62M | -3.47M | -3.32M | -6.97M |
Acquisitions Net | 0 | 19.8M | 7.7M | -818K | 8K | 100K | 100K | 1.8M | 0 | 0 |
Cash generated by investing activities | 109.74M | -138.79M | -29.66M | 12.13M | -17.59M | -107.02M | 118.79M | -75.49M | -56.34M | -6.9M |
Financing activities | ||||||||||
Common Stock Issued | 100.18M | 248.01M | 38.05M | 83.94M | 222.84M | 0 | 196.22M | 0 | 136.25M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -8.18M | -8.44M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 30.16M | 87.05M | 0 | -278.31M | 0 | -932K | -3.63M | -3.54M | 4.58M | -5.79M |
Cash used in financing activities | 136.56M | 331.69M | 29.86M | 331.48M | 221.65M | 1.78M | 195.94M | -2.64M | 142.59M | 229.09M |
Net Change In Cash | 29.73M | -652K | -221.33M | 165.11M | 97.90M | -209.49M | 219.39M | -137.96M | 30.58M | 167.11M |
Cash at end of period | 144.74M | 115.01M | 115.66M | 337.00M | 171.89M | 73.98M | 283.47M | 64.08M | 201.61M | 171.03M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |